

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

INNOVATIVE CHEMICAL DRUG SYH2083 EYE DROPS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2083 eye drops (the “**Product**”), a Class 1 innovative chemical drug developed by the Group, have obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is a small molecule ophthalmic preparation with a novel mechanism of action, which is capable of reducing the adhesion and activation of T lymphocytes and lowering pro-inflammatory signals to treat ocular surface inflammation-related diseases. Preclinical studies demonstrated that the Product exhibited significant pharmacodynamic activity in mouse dry eye models with a well-defined mechanism of action, indicating promising potential for clinical development.

The indication for the approved clinical trial is dry eye disease, and the Product also possesses the clinical potential to be expanded to other inflammatory ocular surface diseases, such as allergic conjunctivitis, in the future. The clinical trial approval of the Product will further enrich the Group’s innovative drug product pipeline in the field of ophthalmology.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 8 September 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.